Millenium Biologix Corporation
Kingston, ON
Company Overview
Millenium Biologix Corporation (TSX: MBC) is a leading biomedical company focused on the development and commercialization of next generation, implantable medical devices and skeletal tissue regeneration products for targeted orthopedic uses. These products, used alone or in combination configurations, promote the repair and natural healing of human bone and other skeletal tissues such as cartilage.
Milleniums strength in developing leading treatments for regenerative medicine is based on its successful integration of three core competencies in advanced biomaterials, biologics and engineering. Skelite, Milleniums synthetic bone graft, was launched for commercial sale in June 2003. Primacoll, Peptos and ACTES (Autologous Tissue Engineering Systems), Milleniums products addressing the clinical orthopedic and tissue engineering markets, are currently in late stage development.
Company Information
Physical Address
785 Midpark Dr
Kingston, ON K7M 7G3
CA
Mailing Address
785 Midpark Dr
Kingston, ON K7M 7G3
CA
Additional Details
Legal Name: Millenium Biologix Corporation
Number of Employees: 57
Total Sales ($CDN): $100,000 - $200,000
CA
Contacts
Sydney Pugh
Title: Chief Executive Officer
Area of Responsibility: Management Executive
Phone: Show phone
Fax: Show fax
Email: Show email
Ian Malone
Title: Chief Financial Officer
Area of Responsibility: Management Executive
Phone: Show phone
Fax: Show fax
Email: Show email
Timothy J. N. Smith
Title: President
Area of Responsibility: Management Executive
Phone: Show phone
Fax: Show fax
Email: Show email
Products
-
Autologous Tissue Engineering Systems (actes)
Millenium's automated cell culture and tissue engineering system, ACTES, will offer an attractive alternative to the current uneconomical business model for cell therapy and is expected to become the international standard in this new field of medical practice. ACTES will provide automated end-to-end control over the full biological process of tissue engineering, from biopsy to tissue creation, within clinics and hospitals directly at the point of care. It enables autologous cell and tissue production in a disposable, patient-dedicated bioreactor system, which is more cost-effective than the current model for cell therapy. Specific versions of the ACTES system optionally incorporate both Skelite and Peptos for enhanced performance and efficacy. Millenium believes that the ACTES system will form the core of the first economically viable tissue engineering business model suitable for widespread clinical use.
-
Bone And Cartilage Stimulating Peptides (bcsp)
When approved, there is a clear opportunity for Millenium's BCSP technology to offer an attractive alternative to recombinant Bone Morphogenic Proteins (BMPs) and other orthobiological growth factors. Primacoll and Peptos are synthetically manufactured small peptides that stimulate targeted bone or cartilage tissue growth. These small entities, unlike the larger protein growth factors currently available for use, have specific binding strategies with directed mechanisms of action that provide greater tissue specificity. Millenium's peptides can be manufactured by way of more simple and reliable, cost-effective chemical synthesis that the company believes will allow Primacoll and Peptos to be used in a broad range of orthopedic and dental applications.
- Skelite Synthetic Bone Graft
NAICS Categories
Additional Information
325410
Algeria, Australia, Czech Republic, Denmark, Finland, France, Germany, Hong Kong, Iceland, Japan, Korea, South, Netherlands, Norway, Sweden, Switzerland, United Kingdom, United States
Argentina, Belgium, Brazil, China, Greece, Ireland, Republic of (EIRE), Italy, Luxembourg, Mexico, New Zealand, Portugal, Russian Federation, South Africa, Spain, Taiwan